Everest Medicines Ltd.
33.98
HKD
-2.08
(-5.77%)
ISIN
KYG3224E1061
CUSIP
G3224E106
Return %
Stock
S&P 500
1Y
-31.93
14.20
3Y
44.60
81.12
5Y
-26.92
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yong Qing Luo
- Full Time Employees
- 812
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- AIA Financial Center, 17/F Shanghai SH China 200082
- IPO Date
- Oct 9, 2020
- Website
- everestmedicines.com
- Similar Companies
- Business
- Everest Medicines Limited (HKEX: 1952.HK) is a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of transformative therapies and vaccines addressing unmet medical needs in renal, infectious, autoimmune, oncology, and ophthalmology indications primarily in Greater China and other Asia Pacific markets; its core commercialized products include NEFECON (etrasimod) for IgA nephropathy, the first etiological treatment approved in China, the US, and Europe, XERAVA (eravacycline) for complicated intra-abdominal infections caused by gram-positive, gram-negative, and anaerobic pathogens including multidrug-resistant strains, and VELSIPITY (etrasimod), an S1P receptor modulator for moderately to severely active ulcerative colitis with NDA pending approval in mainland China in the first half of 2026; late-stage pipeline assets encompass Cefepime-taniborbactam for complicated urinary tract infections, EVER001 (civorebrutinib), a next-generation covalent reversible BTK inhibitor for autoimmune renal diseases including primary membranous nephropathy and lupus nephritis, EVER206 (polymyxin derivative) for multidrug-resistant gram-negative infections, and VIS-101, a bifunctional antibody for retinal diseases; the company advances proprietary platforms including AI-powered mRNA therapeutic cancer vaccines such as EVM14 (TAA vaccine) with US IND cleared and China IND accepted in 2025, mRNA in vivo CAR-T for cancer and autoimmune applications with preclinical milestones expected in late 2025, and in vivo CAR-T programs like EVM16 with first patient dosed in investigator-initiated trials in 2025. Founded in 2017 and headquartered at 16/F, CITIC Pacific Plaza, 1168 West Nanjing Road, Shanghai, China, Everest Medicines employs a dual-engine strategy combining a commercialization platform anchored by NEFECON, VELSIPITY, XERAVA, and supporting assets projecting peak sales exceeding RMB 25 billion globally with in-house innovation in mRNA and CAR-T platforms for long-term growth. Recent developments include NMPA approval in August 2025 for NEFECON production expansion to meet rising demand, localized VELSIPITY manufacturing launch at Jiashan site in March 2025, an exclusive licensing agreement in October 2025 with Visara for VIS-101 rights in Greater China, Singapore, South Korea, and other Asian countries marking entry into ophthalmology with upfront payments and milestones up to US$96 million plus royalties, a US$30.9 million strategic equity investment in August 2025 in I-Mab to bolster oncology synergies with givastomig and 4-1BB platforms, board changes effective October 2025 re-designating Wei Fu as chairman, and 2025 interim results highlighting RMB446 million revenue from NEFECON and XERAVA alongside global Phase II basket trial initiation planned for early 2026.